Genesis CEO, Conrad Mielcuszny, said: “The situation is rapidly changing and is resulting in challenges for organisations across the world. Our priority is to safeguard the health of our employees and maintain business continuity, and as such, we have established Covid-19 teams to oversee our response and contingency planning. These teams are actively monitoring disease progression in each country, WHO guidance, supplier and supply chain risks and prevention and containment measures, while also testing business contingency plans and building stock to ensure that we can maintain supply and delivery.
“We currently have good stocks of raw materials across all our sites and none of our customer orders have been impacted. However, this is a dynamic situation and our commercial and production teams are working to identify any potential impacts and we will liaise closely with customers should shortages or logistics complexity impact any deliveries in the weeks ahead.
“We have been taking additional measures to help prevent infections at our facilities in both Georgia and Cardiff, and are implementing policies to protect all our employees and help minimise the spread of the virus. These include, where possible, enabling employees to work from home, cancelling attendance to large group gatherings, restricting visitors and encouraging our teams to utilise technology as a substitute for in-person meetings. We have also implemented staff travel restrictions and banned business air travel. At all times we are complying with local safety standards and guidance as a minimum and exceeding these as we think appropriate.
“Genesis Biosciences will continue to take appropriate measures during this event to ensure our operations both in the USA and Europe continue running. We will continue to monitor the situation as it develops and adapt our processes and procedures to fulfil our commitments and keep all of our stakeholders safe and healthy at this challenging time.”
